Brief: Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million
01/05/2025 12:00
May 01 (Reuters) - Amicus Therapeutics Q1 operating expenses USD 121.5 million. Q1 adjusted operating expenses USD 94.5 million Q1 EPS USD -0.07 Q1 net income USD -21.7 million
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates